The promise of second-generation PI3K inhibitors for CLL

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.

Share this video  
Similar topics